Acute hypertension after renal allograft rejection therapy with OKT3 monoclonal antibody.
Acute rejection of renal allografts was treated with the monoclonal antibody OKT3 given intravenously. A variety of adverse events were observed on days 1 and 2 following treatment with 5 mg/day OKT3 for 10 days including heart failure, pulmonary oedema and hypertension. Continuous monitoring of 19 patients treated with OKT3 for acute renal allograft rejection detected a transient increase, lasting 2 h, in systolic and diastolic blood pressures on day 1. A larger increase in systolic and diastolic pressures lasting 11-13 h was observed on day 2. Treatment with 5 mg OKT3 on day 3 did not significantly increase systolic or diastolic pressure. It is concluded that OKT3 can aggravate hypertension and hypertensive emergencies may be encountered during the initial phase of OKT3 treatment.
Spieker
C
C
Medical Clinic, Wilhelms University, Munster, FRG.
Zidek
W
W
Barenbrock
M
M
Wieneke
R
R
Buchholz
B
B
Rahn
K H
KH
D000208:Acute Disease; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006084:Graft Rejection / Q000187:drug effects; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000209:etiology*; D007275:Injections, Intravenous; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D016853:Muromonab-CD3 / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use
D016853:Muromonab-CD3; D011239:Prednisolone